Harold R. Roberts Distinguished Professor, Division of Hematology/Oncology, Department of Medicine, 932 Mary Ellen Jones Bldg, CB #7035, Chapel Hill, NC 27599, USA.
Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):372-5. doi: 10.1161/ATVBAHA.109.197145. Epub 2010 Feb 5.
Venous thromboembolism, comprising deep vein thrombosis and pulmonary embolism, is a common disorder with at least 250 000 new events occurring each year in the United States alone. Treatment of venous thromboembolism includes anticoagulation, which is achieved initially with the use of a parenterally administered agent followed by a more prolonged course of treatment with an oral vitamin K antagonist. The duration of treatment depends on the clinical assessment of the benefit-to-risk ratio of prolonged anticoagulation versus the risk of recurrent events. In this review, we discuss some of the issues that we believe are among the most critical unanswered questions in the management of venous thromboembolism in the present era.
静脉血栓栓塞症,包括深静脉血栓形成和肺栓塞,是一种常见疾病,仅在美国每年就至少有 25 万例新发病例。静脉血栓栓塞症的治疗包括抗凝治疗,最初采用肠外给予的药物,然后采用更长期的口服维生素 K 拮抗剂治疗。治疗持续时间取决于对延长抗凝治疗的获益-风险比与复发事件风险的临床评估。在这篇综述中,我们讨论了一些我们认为在当前时代管理静脉血栓栓塞症中最重要的未解决问题。